PEN Stock Analysis
PE
Neutral
Based on Eyestock quantitative analysis, PEN`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 3,900 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. The company has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The firm's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The firm sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.